FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Other Events
Item 8.01.
| Press Release dated February 28, 2020 |
FENNEC PHARMACEUTICALS INC. Exhibit
EX-99.1 2 tm2011226d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park,…
To view the full exhibit click here
About FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF)
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.